The fact that CHD4/NuRD appears to function in an oncogenic fashion in some instances (e.g. p53 deacetylation), whereas CHD4 exerts a tumour-suppressor function in others (e.g. through amplification of the DDR) may mean that deletions or amplifications of key component genes may have different effects in different tumour types. This evidence concerns the gene TP53 and neoplasm.